New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Phase III data over two years demonstrates Susvimo's potential as an alternative to eye injections for treating diabetic macular edema (DME) and diabetic retinopathy (DR). The efficacy and safety results remained consistent with the known safety profile for Susvimo in people with DME and DR. Susvimo offers continuous delivery of ranibizumab to the eye through a refillable implant, providing sustained visual acuity improvements and reduced macular edema over two years. The US FDA has accepted Roche's supplemental Biologics License Application (sBLA) for Susvimo in DME and DR based on one-year data from the Pagoda and Pavilion studies. Susvimo is currently approved in the US for the treatment of neovascular or 'wet' age-related macular degeneration (nAMD). If approved by the US FDA, Susvimo could revolutionize the treatment of diabetic eye diseases, potentially preserving vision and reducing the need for frequent injections. The findings emphasize the potential of Susvimo as a convenient and effective long-term treatment option for people with DME and DR, offering them improved vision outcomes and the possibility of maintaining their independence.